Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Caruso, A
Right arrow Articles by Di Simone, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caruso, A
Right arrow Articles by Di Simone, N
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction Update, Vol.5, No.3 pp.267-276, 1999
© European Society of Human Reproduction and Embryology 1999; all rights reserved

Antiphospholipid antibodies in obstetrics: new complexities and sites of action

A Caruso0, S De Carolis and N Di Simone

Department of Obstetrics and Gynecology, Universita' Cattolica del S. Cuore, Largo A. Gemelli 8, 00168 Rome, Italy 0 Corresponding author

Abstract

The antiphospholipid syndrome, the cause of which remains unknown, is characterized by severe pregnancy complications. Fetal losses have been attributed to thrombosis of the uteroplacental vasculature and placental infarction. Polyclonal and monoclonal antiphospholipid antibodies seem able to recognize a 'plasma cofactor' on the endothelial and trophoblast cell surfaces and to affect cell function, inducing a procoagulant state. Although thrombosis is observed frequently in the decidua and placentas of patients with antiphospholipid antibodies, this observation was not universal, nor present in a sufficient degree to account for the pregnancy loss associated with this syndrome. Recent observations have suggested that antiphospholipid antibodies decreased placental hormone production and trophoblast intercellular fusion and invasion, suggesting that many of the obstetric complications observed in the syndrome may be due to antiphospholipid antibody-induced trophoblast dysfunction. However, the complex antigens on the trophoblast surfaces are still to be characterized and correlated with clinical manifestation. It is clear that successful pregnancies with the syndrome are more likely to occur after maternal treatment. Although prednisone may still be needed to treat manifestations associated with autoimmune disorders, the use of heparin, together with low-dose aspirin, has replaced prednisone for treatment of pregnant women. Maternal treatment and careful monitoring of fetal well-being are mandatory in the management of these high-risk pregnancies.

Keywords:antiphospholipid syndrome/fetal loss/phospholipid antibodies/placental thrombosis/trophoblast invasiveness


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
LupusHome page
G Moroni and C Ponticelli
Pregnancy after lupus nephritis
Lupus, January 1, 2005; 14(1): 89 - 94.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
L. Heilmann, G.-F. v. Tempelhoff, and K. Pollow
Antiphospholipid Syndrome in Obstetrics
Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 143 - 150.
[Abstract] [PDF]


Home page
Hum ReprodHome page
S. B. Cohen, M. Goldenberg, J. Rabinovici, A. L. Lidor, M. Dulitzky, B. Gilburd, Y. Shoenfeld, and E. Schiff
Anti-cardiolipin antibodies in fetal blood and amniotic fluid derived from patients with the anti-phospholipid syndrome
Hum. Reprod., May 1, 2000; 15(5): 1170 - 1172.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.